The effect of allopurinol on cardiovascular outcomes in patients with type 2 diabetes: a systematic review.
Allopurinol
Atherosclerosis oxidative stress
Cardiovascular disease
Inflammation
Type 2 diabetes
Journal
Hormones (Athens, Greece)
ISSN: 2520-8721
Titre abrégé: Hormones (Athens)
Pays: Switzerland
ID NLM: 101142469
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
03
05
2022
accepted:
27
09
2022
pubmed:
6
10
2022
medline:
3
12
2022
entrez:
5
10
2022
Statut:
ppublish
Résumé
Cardiovascular disease (CVD) remains the main cause of death in patients with type 2 diabetes (T2D). Although hyperuricemia has been associated with multiple CV complications, it is not officially recognized as a target parameter for CVD risk reduction. To systematically review the literature in order to determine whether treating hyperuricemia with allopurinol in patients with T2D reduces CVD risk. A thorough literature search in the PubMed, CENTRAL, and EMBASE databases from inception to August 2022 was performed. After application of selection criteria, 6 appropriate studies were identified. Detailed analysis of the data derived indicated that there is an association between allopurinol treatment and CV benefits, resulting in a reduced risk of CVD events and mortality rates. This association can be attributed mainly to the reduction of inflammation and oxidative burden, as well as to the improvement of glycemic and lipid profiles. This systematic review provides evidence that allopurinol may reduce CVD risk in patients with T2D. Randomized, placebo-controlled trials should be performed in order to confirm these findings and identify specific subgroups of patients who will benefit most.
Sections du résumé
BACKGROUND
BACKGROUND
Cardiovascular disease (CVD) remains the main cause of death in patients with type 2 diabetes (T2D). Although hyperuricemia has been associated with multiple CV complications, it is not officially recognized as a target parameter for CVD risk reduction.
AIM
OBJECTIVE
To systematically review the literature in order to determine whether treating hyperuricemia with allopurinol in patients with T2D reduces CVD risk.
METHODS
METHODS
A thorough literature search in the PubMed, CENTRAL, and EMBASE databases from inception to August 2022 was performed. After application of selection criteria, 6 appropriate studies were identified.
RESULTS
RESULTS
Detailed analysis of the data derived indicated that there is an association between allopurinol treatment and CV benefits, resulting in a reduced risk of CVD events and mortality rates. This association can be attributed mainly to the reduction of inflammation and oxidative burden, as well as to the improvement of glycemic and lipid profiles.
CONCLUSIONS
CONCLUSIONS
This systematic review provides evidence that allopurinol may reduce CVD risk in patients with T2D. Randomized, placebo-controlled trials should be performed in order to confirm these findings and identify specific subgroups of patients who will benefit most.
Identifiants
pubmed: 36197637
doi: 10.1007/s42000-022-00403-9
pii: 10.1007/s42000-022-00403-9
doi:
Substances chimiques
Allopurinol
63CZ7GJN5I
Blood Glucose
0
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
599-610Informations de copyright
© 2022. The Author(s), under exclusive licence to Hellenic Endocrine Society.
Références
Townsend N, Kazakiewicz D, Lucy Wright F et al (2022) Epidemiology of cardiovascular disease in Europe. Nat Rev Cardiol 19:133–143. https://doi.org/10.1038/s41569-021-00607-3
doi: 10.1038/s41569-021-00607-3
pubmed: 34497402
Timmis A, Townsend N, Gale CP et al (2020) European Society of Cardiology: cardiovascular disease statistics 2019 (Executive Summary). Eur Heart J 41:12–85. https://doi.org/10.1093/eurheartj/ehz859
doi: 10.1093/eurheartj/ehz859
pubmed: 31820000
Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ (2019) Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail 21:1306–1325. https://doi.org/10.1002/ejhf.1594
doi: 10.1002/ejhf.1594
pubmed: 31523902
Pradeepa R, Mohan V (2017) Prevalence of type 2 diabetes and its complications in India and economic costs to the nation. Eur J Clin Nutr 71:816–824. https://doi.org/10.1038/ejcn.2017.40
doi: 10.1038/ejcn.2017.40
pubmed: 28422124
Federation ID. IDF Diabetes Atlas - 10th Edition n.d. https://diabetesatlas.org/atlas/tenth-edition/ Accessed 8 July 2022.
Cosentino F, Grant PJ, Aboyans V et al (2020) 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41:255–323. https://doi.org/10.1093/eurheartj/ehz486
doi: 10.1093/eurheartj/ehz486
pubmed: 31497854
Siasos G, Bletsa E, Stampouloglou PK et al (2020) Novel antidiabetic agents: cardiovascular and safety outcomes. Curr Pharm Des 26:5911–5932. https://doi.org/10.2174/1381612826666201109110107
doi: 10.2174/1381612826666201109110107
pubmed: 33167826
Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128. https://doi.org/10.1056/NEJMoa1504720
doi: 10.1056/NEJMoa1504720
pubmed: 26378978
Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322. https://doi.org/10.1056/NEJMoa1603827
doi: 10.1056/NEJMoa1603827
pubmed: 27295427
pmcid: 4985288
Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657. https://doi.org/10.1056/NEJMoa1611925
doi: 10.1056/NEJMoa1611925
pubmed: 28605608
Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347–357. https://doi.org/10.1056/NEJMoa1812389
doi: 10.1056/NEJMoa1812389
pubmed: 30415602
Husain M, Birkenfeld AL, Donsmark M et al (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381:841–851. https://doi.org/10.1056/NEJMoa1901118
doi: 10.1056/NEJMoa1901118
pubmed: 31185157
Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844. https://doi.org/10.1056/NEJMoa1607141
doi: 10.1056/NEJMoa1607141
pubmed: 27633186
Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial. Lancet 394:121–130. https://doi.org/10.1016/S0140-6736(19)31149-3
doi: 10.1016/S0140-6736(19)31149-3
pubmed: 31189511
Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306. https://doi.org/10.1056/NEJMoa1811744
doi: 10.1056/NEJMoa1811744
pubmed: 30990260
Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392:1519–1529. https://doi.org/10.1016/S0140-6736(18)32261-X
doi: 10.1016/S0140-6736(18)32261-X
pubmed: 30291013
Paschou SA, Siasos G, Bletsa E et al (2020) The effect of DPP-4i on endothelial function and arterial stiffness in patients with type 2 diabetes: a systematic review of randomized placebo-controlled trials. Curr Pharm Des 26:5980–5987. https://doi.org/10.2174/1381612826666200417153241
doi: 10.2174/1381612826666200417153241
pubmed: 32303166
Batzias K, Antonopoulos AS, Oikonomou E et al (2018) Effects of newer antidiabetic drugs on endothelial function and arterial stiffness: a systematic review and meta-analysis. J Diabete Res 2018:1–10. https://doi.org/10.1155/2018/1232583
doi: 10.1155/2018/1232583
Siasos G, Stampouloglou PK, Bletsa E et al (2020) SGLT-2i and cardiovascular prognosis. Curr Pharm Des 26:3905–3907. https://doi.org/10.2174/138161282632200811172751
doi: 10.2174/138161282632200811172751
pubmed: 33001001
Committee ADAPP, Draznin B, Aroda VR et al (2022) 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care 45:S125–S143. https://doi.org/10.2337/dc22-S009
doi: 10.2337/dc22-S009
Aung T, Myung G, FitzGerald J (2017) Treatment approaches and adherence to urate-lowering therapy for patients with gout. Patient Prefer Adherence 11:795–800. https://doi.org/10.2147/PPA.S97927
doi: 10.2147/PPA.S97927
pubmed: 28458524
pmcid: 5403120
Dehlin M, Jacobsson L, Roddy E (2020) Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 16:380–390. https://doi.org/10.1038/s41584-020-0441-1
doi: 10.1038/s41584-020-0441-1
pubmed: 32541923
McDonagh EM, Thorn CF, Callaghan JT, Altman RB, Klein TE (2014) PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics. Pharmacogenet Genomics 24:464–476. https://doi.org/10.1097/FPC.0000000000000058
doi: 10.1097/FPC.0000000000000058
pubmed: 24915143
pmcid: 4122637
Mende C (2015) Management of chronic kidney disease: the relationship between serum uric acid and development of nephropathy. Adv Ther 32:1177–1191. https://doi.org/10.1007/s12325-015-0272-7
doi: 10.1007/s12325-015-0272-7
pubmed: 26650815
pmcid: 4679778
Becker MA, Schumacher HR, Wortmann RL et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450–2461. https://doi.org/10.1056/NEJMoa050373
doi: 10.1056/NEJMoa050373
pubmed: 16339094
Shimizu T, Hori H, Umeyama M, Shimizu K (2019) Characteristics of gout patients according to the laterality of nephrolithiasis: a cross-sectional study using helical computed tomography. Int J Rheum Dis 22:567–573. https://doi.org/10.1111/1756-185X.13443
doi: 10.1111/1756-185X.13443
pubmed: 30485677
Krishnan E (2009) Hyperuricemia and incident heart failure. Circ Heart Fail 2:556–562. https://doi.org/10.1161/CIRCHEARTFAILURE.108.797662
doi: 10.1161/CIRCHEARTFAILURE.108.797662
pubmed: 19919980
pmcid: 2801811
Chao T-F, Liu C-J, Chen S-J et al (2014) Hyperuricemia and the risk of ischemic stroke in patients with atrial fibrillation — could it refine clinical risk stratification in AF? Int J Cardiol 170:344–349. https://doi.org/10.1016/j.ijcard.2013.11.011
doi: 10.1016/j.ijcard.2013.11.011
pubmed: 24290426
Huang C-C, Huang P-H, Chen J-H et al (2015) An independent risk of gout on the development of deep vein thrombosis and pulmonary embolism. Medicine (Baltimore) 94:e2140. https://doi.org/10.1097/MD.0000000000002140
doi: 10.1097/MD.0000000000002140
pubmed: 26705202
Chen J-H, Pan W-H, Hsu C-C et al (2013) Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: a prospective study. Arthritis Care Res (Hoboken) 65:133–140. https://doi.org/10.1002/acr.21824
doi: 10.1002/acr.21824
pubmed: 22933424
Zhu J, Qi X, Tan Y, Lyu X (2016) Dietary factors associated with hyperuricemia and glycolipid metabolism disorder in middle-aged and elderly people. Sichuan Da Xue Xue Bao Yi Xue Ban 47:68–72
pubmed: 27062785
Roughley MJ, Belcher J, Mallen CD, Roddy E (2015) Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther 17:90. https://doi.org/10.1186/s13075-015-0610-9
doi: 10.1186/s13075-015-0610-9
pubmed: 25889144
pmcid: 4404569
Suliman ME, Johnson RJ, García-López E et al (2006) J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis 48:761–771. https://doi.org/10.1053/j.ajkd.2006.08.019
doi: 10.1053/j.ajkd.2006.08.019
pubmed: 17059995
Kuwabara M (2015) Hyperuricemia, cardiovascular disease, and hypertension. Pulse (Basel) 3:242–252. https://doi.org/10.1159/000443769
doi: 10.1159/000443769
Lv Q, Meng X-F, He F-F et al (2013) High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS ONE 8:e56864. https://doi.org/10.1371/journal.pone.0056864
doi: 10.1371/journal.pone.0056864
pubmed: 23437258
pmcid: 3577701
Kushiyama A (2014) Linking uric acid metabolism to diabetic complications. World J Diabetes 5:787. https://doi.org/10.4239/wjd.v5.i6.787
doi: 10.4239/wjd.v5.i6.787
pubmed: 25512781
pmcid: 4265865
Weisman A, Tomlinson GA, Lipscombe LL, Perkins BA, Hawker GA (2019) Association between allopurinol and cardiovascular outcomes and all-cause mortality in diabetes: a retrospective, population-based cohort study. Diabetes Obes Metab 21:1322–1329. https://doi.org/10.1111/dom.13656
doi: 10.1111/dom.13656
pubmed: 30734980
Singh JA, Ramachandaran R, Yu S, Curtis JR (2017) Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes. BMC Cardiovasc Disord 17:76. https://doi.org/10.1186/s12872-017-0513-6
doi: 10.1186/s12872-017-0513-6
pubmed: 28288564
pmcid: 5348884
Liu P, Wang H, Zhang F, Chen Y, Wang D, Wang Y (2015) The effects of allopurinol on the carotid intima-media thickness in patients with type 2 diabetes and asymptomatic hyperuricemia: a three-year randomized parallel-controlled study. Intern Med 54:2129–2137. https://doi.org/10.2169/internalmedicine.54.4310
doi: 10.2169/internalmedicine.54.4310
pubmed: 26328636
Szwejkowski BR, Gandy SJ, Rekhraj S et al (2013) Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. J Am Coll Cardiol 62:2284–2293. https://doi.org/10.1016/j.jacc.2013.07.074
doi: 10.1016/j.jacc.2013.07.074
pubmed: 23994420
Dogan A, Yarlioglues M, Kaya MG et al (2011) Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Press 20:182–187. https://doi.org/10.3109/08037051.2010.538977
doi: 10.3109/08037051.2010.538977
pubmed: 21133824
Butler R, Morris AD, Belch JJF, Hill A, Struthers AD (2000) Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 35:746–751. https://doi.org/10.1161/01.HYP.35.3.746
doi: 10.1161/01.HYP.35.3.746
pubmed: 10720589
Gæde P, Lund-Andersen H, Parving H-H, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591. https://doi.org/10.1056/NEJMoa0706245
doi: 10.1056/NEJMoa0706245
pubmed: 18256393
Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241. https://doi.org/10.1038/nature04516
doi: 10.1038/nature04516
pubmed: 16407889
Kanellis J, Watanabe S, Li JH et al (2003) Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41:1287–1293. https://doi.org/10.1161/01.HYP.0000072820.07472.3B
doi: 10.1161/01.HYP.0000072820.07472.3B
pubmed: 12743010
Kang D-H, Park S-K, Lee I-K, Johnson RJ (2005) Uric acid–induced c-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 16:3553–3562. https://doi.org/10.1681/ASN.2005050572
doi: 10.1681/ASN.2005050572
pubmed: 16251237
Corry DB, Eslami P, Yamamoto K et al (2008) Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin–angiotensin system. J Hypertens 26:269–275. https://doi.org/10.1097/HJH.0b013e3282f240bf
doi: 10.1097/HJH.0b013e3282f240bf
pubmed: 18192841
Yu M-A, Sánchez-Lozada LG, Johnson RJ, Kang D-H (2010) Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 28:1234–1242
doi: 10.1097/HJH.0b013e328337da1d
pubmed: 20486275
Schwartz IF, Grupper A, Chernichovski T et al (2011) Hyperuricemia attenuates aortic nitric oxide generation, through inhibition of arginine transport, in rats. J Vasc Res 48:252–260. https://doi.org/10.1159/000320356
doi: 10.1159/000320356
pubmed: 21099230
Mazzali M, Hughes J, Kim Y-G et al (2001) Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38:1101–1106. https://doi.org/10.1161/hy1101.092839
doi: 10.1161/hy1101.092839
pubmed: 11711505
Zatz R, Meyer TW, Rennke HG, Brenner BM (1985) Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 82:5963–5967. https://doi.org/10.1073/pnas.82.17.5963
doi: 10.1073/pnas.82.17.5963
pubmed: 3862110
pmcid: 390674
Sánchez-Lozada LG, Lanaspa MA, Cristóbal-García M, et, (2012) uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol 121:e71–e78. https://doi.org/10.1159/000345509
doi: 10.1159/000345509
pubmed: 23235493
Ginsberg MH, Kozin F, O’Malley M, McCarty DJ (1977) Release of platelet constituents by monosodium urate crystals. J Clin Invest 60:999–1007. https://doi.org/10.1172/JCI108880
doi: 10.1172/JCI108880
pubmed: 908764
pmcid: 372451
Samuel VT, Petersen KF, Shulman GI (2010) Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375:2267–77. https://doi.org/10.1016/S0140-6736(10)60408-4
doi: 10.1016/S0140-6736(10)60408-4
pubmed: 20609972
pmcid: 2995547
Choi JWJ, Ford ES, Gao X, Choi HK (2008) Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the third national health and nutrition examination survey. Arthritis Rheum 59:109–116. https://doi.org/10.1002/art.23245
doi: 10.1002/art.23245
pubmed: 18163396
Tassone EJ, Cimellaro A, Perticone M et al (2018) Uric acid impairs insulin signaling by promoting Enpp1 binding to insulin receptor in human umbilical vein endothelial cells. Front Endocrinol (Lausanne) 9:98. https://doi.org/10.3389/fendo.2018.00098
doi: 10.3389/fendo.2018.00098
pubmed: 29619007
Zoppini G, Targher G, Negri C et al (2009) Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients. Diabetes Care 32:1716–1720. https://doi.org/10.2337/dc09-0625
doi: 10.2337/dc09-0625
pubmed: 19542211
pmcid: 2732164
Singh JA, Yu S (2016) Allopurinol reduces the risk of myocardial infarction (MI) in the elderly: a study of Medicare claims. Arthritis Res Ther 18:209. https://doi.org/10.1186/s13075-016-1111-1
doi: 10.1186/s13075-016-1111-1
pubmed: 27655429
pmcid: 5032238
Grimaldi-Bensouda L, Alpérovitch A, Aubrun E et al (2015) Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis 74:836–842. https://doi.org/10.1136/annrheumdis-2012-202972
doi: 10.1136/annrheumdis-2012-202972
pubmed: 24395556
Wei L, Mackenzie IS, Chen Y, Struthers AD, MacDonald TM (2011) Impact of allopurinol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol 71:600–607. https://doi.org/10.1111/j.1365-2125.2010.03887.x
doi: 10.1111/j.1365-2125.2010.03887.x
pubmed: 21395653
pmcid: 3080649
Søltoft Larsen K, Pottegård A, Lindegaard HM, Hallas J (2016) Impact of urate level on cardiovascular risk in allopurinol treated patients. A nested case-control study PLOS ONE 11:e0146172. https://doi.org/10.1371/journal.pone.0146172
doi: 10.1371/journal.pone.0146172
pubmed: 26751377
van der Pol KH, Wever KE, Verbakel M et al (2021) Allopurinol to reduce cardiovascular morbidity and mortality: a systematic review and meta-analysis. PLoS ONE 16:e0260844. https://doi.org/10.1371/journal.pone.0260844
doi: 10.1371/journal.pone.0260844
pubmed: 34855873
pmcid: 8638940
George J, Carr E, Davies J, Belch JJF, Struthers A (2006) High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114:2508–2516. https://doi.org/10.1161/CIRCULATIONAHA.106.651117
doi: 10.1161/CIRCULATIONAHA.106.651117
pubmed: 17130343
Rekhraj S, Gandy SJ, Szwejkowski BR et al (2013) High dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol 61:926–932. https://doi.org/10.1016/j.jacc.2012.09.066
doi: 10.1016/j.jacc.2012.09.066
pubmed: 23449426
Rajendra NS, Ireland S, George J et al (2011) Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol 58:820–828. https://doi.org/10.1016/j.jacc.2010.12.052
doi: 10.1016/j.jacc.2010.12.052
pubmed: 21835317
Day RO, Kannangara DRW, Stocker SL et al (2017) Allopurinol: insights from studies of dose-response relationships. Expert Opin Drug Metab Toxicol 13:449–462. https://doi.org/10.1080/17425255.2017.1269745
doi: 10.1080/17425255.2017.1269745
pubmed: 27927043
Stamp LK, Barclay ML, O’Donnell JL et al (2011) Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clin Pharmacol Ther 90:392–398. https://doi.org/10.1038/clpt.2011.113
doi: 10.1038/clpt.2011.113
pubmed: 21796116
Yun J, Mattsson J, Schnyder K et al (2013) Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clin Exp Allergy 43:1246–1255. https://doi.org/10.1111/cea.12184
doi: 10.1111/cea.12184
pubmed: 24152157
Ramasamy SN, Korb-Wells CS, Kannangara DRW et al (2013) Allopurinol hypersensitivity: a systematic review of all published cases, 1950–2012. Drug Saf 36:953–980. https://doi.org/10.1007/s40264-013-0084-0
doi: 10.1007/s40264-013-0084-0
pubmed: 23873481
Higgins P, Dawson J, Lees KR et al (2012) Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther 30:217–226. https://doi.org/10.1111/j.1755-5922.2011.00277.x
doi: 10.1111/j.1755-5922.2011.00277.x
pubmed: 22099531
Engberding N, Spiekermann S, Schaefer A et al (2004) Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction. Circulation 110:2175–2179. https://doi.org/10.1161/01.CIR.0000144303.24894.1C
doi: 10.1161/01.CIR.0000144303.24894.1C
pubmed: 15466649
Kao MP, Ang DS, Gandy SJ et al (2011) Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 22:1382–1389. https://doi.org/10.1681/ASN.2010111185
doi: 10.1681/ASN.2010111185
pubmed: 21719783
pmcid: 3137586
Dawson A, Morris AD, Struthers AD (2005) The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus. Diabetologia 48:1971–1979. https://doi.org/10.1007/s00125-005-1896-y
doi: 10.1007/s00125-005-1896-y
pubmed: 16094529
Liao Y, Cooper RS, McGee DL et al (1995) The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 273:1592–1597
doi: 10.1001/jama.1995.03520440046035
pubmed: 7745772
Opherk D, Mall G, Zebe H et al (1984) Reduction of coronary reserve: a mechanism for angina pectoris in patients with arterial hypertension and normal coronary arteries. Circulation 69:1–7. https://doi.org/10.1161/01.CIR.69.1.1
doi: 10.1161/01.CIR.69.1.1
pubmed: 6689632
Ghali JK, Kadakia S, Cooper RS, Liao Y (1991) Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol 17:1277–1282. https://doi.org/10.1016/S0735-1097(10)80135-4
doi: 10.1016/S0735-1097(10)80135-4
pubmed: 1826691
El-Bassossy HM, Elberry AA, Azhar A, Ghareib SA, Alahdal AM (2015) Ameliorative effect of allopurinol on vascular complications of insulin resistance. J Diabetes Res 2015:1–10. https://doi.org/10.1155/2015/178540
doi: 10.1155/2015/178540
Borges RL, Ribeiro AB, Zanella MT, Batista MC (2010) Uric acid as a factor in the metabolic syndrome. Curr Hypertens Rep 12:113–119. https://doi.org/10.1007/s11906-010-0098-2
doi: 10.1007/s11906-010-0098-2
pubmed: 20424936
Hosoya T, Kuriyama S, Yoshizawa T et al (2012) Effects of combined antihypertensive therapy with losartan/hydrochlorothiazide on uric acid metabolism. Intern Med 51:2509–2514. https://doi.org/10.2169/internalmedicine.51.7584
doi: 10.2169/internalmedicine.51.7584
pubmed: 22989819
Elmelegy D, Abhishek A (2021) Reasons for discontinuing urate-lowering treatment in community-dwelling adults with gout: results of a primary care-based cross-sectional study. Rheumatol Adv Pract 5:rkab022. https://doi.org/10.1093/rap/rkab022
Suissa S, Suissa K, Hudson M (2022) Allopurinol and cardiovascular events: time-related biases in observational studies. Arthritis Care Res (Hoboken) 74:858–865. https://doi.org/10.1002/acr.24713
doi: 10.1002/acr.24713
pubmed: 34057310
Stamp LK, Taylor WJ, Jones PB et al (2012) Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 64:2529–2536. https://doi.org/10.1002/art.34488
doi: 10.1002/art.34488
pubmed: 22488501
Stamp LK, O’Donnell JL, Zhang M et al (2011) Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 63:412–421. https://doi.org/10.1002/art.30119
doi: 10.1002/art.30119
pubmed: 21279998
Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76:47–56. https://doi.org/10.1016/0002-9343(84)90743-5
doi: 10.1016/0002-9343(84)90743-5
pubmed: 6691361
Biscaglia S, Ceconi C, Malagù M, Pavasini R, Ferrari R (2016) Uric acid and coronary artery disease: an elusive link deserving further attention. Int J Cardiol 213:28–32. https://doi.org/10.1016/j.ijcard.2015.08.086
doi: 10.1016/j.ijcard.2015.08.086
pubmed: 26318389
FitzGerald JD, Dalbeth N, Mikuls T et al (2020) American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken) Arthritis Care Res 72:744–60
doi: 10.1002/acr.24180
Kimura K, Hosoya T, Uchida S et al (2018) Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis 72:798–810. https://doi.org/10.1053/j.ajkd.2018.06.028
doi: 10.1053/j.ajkd.2018.06.028
pubmed: 30177485
Takata T, Isomoto H (2021) Pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: renoprotective mechanisms beyond glycemic control. Int J Mol Sci 22:4374. https://doi.org/10.3390/ijms22094374
doi: 10.3390/ijms22094374
pubmed: 33922132
pmcid: 8122753
Chino Y, Samukawa Y, Sakai S et al (2014) SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 35:391–404. https://doi.org/10.1002/bdd.1909
doi: 10.1002/bdd.1909
pubmed: 25044127
pmcid: 4223977
la Grotta R, de Candia P, Olivieri F et al (2022) Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin. Cell Mol Life Sci 79:273. https://doi.org/10.1007/s00018-022-04289-z
doi: 10.1007/s00018-022-04289-z
pubmed: 35503137
pmcid: 9064844
Zhang J, Ji X, Dong Z et al (2021) Impact of fenofibrate therapy on serum uric acid concentrations: a review and meta-analysis. Endocr J 68:829–837. https://doi.org/10.1507/endocrj.EJ20-0808
doi: 10.1507/endocrj.EJ20-0808
pubmed: 33731500
Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Hada T (2001) Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol. J Rheumatol 28:2294–2297
pubmed: 11669172
Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M (2005) Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 11:4161–4175. https://doi.org/10.2174/138161205774913309
doi: 10.2174/138161205774913309
pubmed: 16375738
Waldman B, Ansquer J-C, Sullivan DR et al (2018) Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. Lancet Diabetes Endocrinol 6:310–318. https://doi.org/10.1016/S2213-8587(18)30029-9
doi: 10.1016/S2213-8587(18)30029-9
pubmed: 29496472
Sutton Burke EM, Kelly TC, Shoales LA, Nagel AK (2020) Angiotensin receptor blockers effect on serum uric acid-a class effect? J Pharm Pract 33:874–881. https://doi.org/10.1177/0897190019866315
doi: 10.1177/0897190019866315
pubmed: 31390929
Sato M, Iwanaga T, Mamada H et al (2008) Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res 25:639–646. https://doi.org/10.1007/s11095-007-9401-6
doi: 10.1007/s11095-007-9401-6
pubmed: 17674156
Smink PA, Bakker SJL, Laverman GD et al (2012) An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials. J Hypertens 30:1022–1028. https://doi.org/10.1097/HJH.0b013e32835200f9
doi: 10.1097/HJH.0b013e32835200f9
pubmed: 22388234